搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
4 天
on MSN
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
FiercePharma
2 天
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
pharmaphorum
4 天
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...
4 天
on MSN
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
FiercePharma
3 天
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
3 天
首款!辉瑞疫苗再获FDA批准
▎药明康德内容团队编辑日前,辉瑞(Pfizer)宣布美国FDA已批准其呼吸道合胞病毒(RSV)疫苗Abrysvo(RSVpreF),用于预防18至59岁高风险个体因RSV引起的下呼吸道疾病(LRTD)。此前,该疫苗已获批用于60岁及以上的成人群体。根 ...
biopharma-reporter
3 天
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
3 天
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...
2 天
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging ...
On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...
BioSpace
3 天
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
7 小时
辉瑞制药针对呼吸道合胞体病毒(RSV)的
辉瑞制药针对呼吸道合胞体病毒(RSV)的疫苗获得美国食品药品管理局(FDA)批准,用于18-59岁年龄段人群接种。
McKnight's Long-Term Care News
3 天
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈